Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer

Oncotarget

Volumn 7, Issue 5, 2016, Pages 5564-5575

  Wang, Jing ^a   Liu, Yao ^a   Wang, Lihua ^a   Sun, Xiao ^a   Wang, Yudong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Endometrial cancer; Metastasis; Prognosis; RANK; RANKL

Indexed keywords

BETA CATENIN; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN KINASE B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR SNAIL; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

AKT PATHWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METASTASIS INHIBITION; MOUSE; MOUSE MODEL; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; ANIMAL; APOPTOSIS; CANCER STAGING; CELL PROLIFERATION; DRUG SCREENING; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PELVIS TUMOR; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PELVIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958078560     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6795     Document Type: Article

References (37)

1. Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin. 2015; 65:5-29.
2. Rasila KK, Burger RA, Smith H, Lee FC, Verschraegen C. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer. 2005; 15:710-726.
3. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3:401-410.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86:353-364.
5. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006; 440:692-696.
6. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate. 2008; 68:92-104.
7. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone. 2007; 40:981-990.
8. Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis. 1993; 11:5-14.
9. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem. 2002; 277:44347-44356.
10. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Bio Chem. 1988; 273:20551-20555.
11. Zhang L, Teng Y, Wang Y, Li W, Shi J, Ma Y, Li C, Shi X, Qu X, Liu Y. The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. Oncotarget. 2015; 6: 22918-22933. doi: 10.18632/oncotarget.4382.
12. Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L. RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells in vitro. Plos one. 2013; 8:e63153.
13. Rosenblatt KA, Thomas DB. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO collaborative study of neoplasia and steroid contraceptives, Int J Cancer. 1991; 49:870-874.
14. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006; 103:535-540.
15. Faigenbaum R, Haklai R, Ben-Baruch G, Kloog Y. Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Oncotarget. 2013; 4:316-328. doi: 10.18632/oncotarget.867.
16. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362: 419-427.
17. Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007; 369:1703-1710.
18. Enserink M, Women's health. The vanishing promises of hormone replacement. Science. 2002; 297:325-326.
19. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010; 468:103-107.
20. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010; 468: 98-102.
21. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011; 29:3278-3285.
22. Wang J, Sun X, Zhang HJ, Wang YD, Li YH. MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer. Oncol Rep. 2015; 33: 799-809.
23. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer. 1997; 79:320-327.
24. Yahata T, Fujita K, Aoki Y, Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod. 2006; 21:1070-1075.
25. Hirahatake K, Hareyama H, Sakuragi N, Nishiya M, Makinoda S, Fujimoto S. A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol. 1997; 65:82-87.
26. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/AKT pathway in cancer. Oncogene. 2008; 27:5511-5526.
27. Brunetti G, Rizzi R, Oranger A, Gigante I, Mori G, Taurini G, Mongelli T, Colaianni G, Di Benedetto A, Tamma R, Ingravallo G, Napoli A, Faienza MF, et al. LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. Oncotarget. 2014; 5:12950-12967. doi: 10.18632/oncotarget.2633.
28. Fang DX, Hawke D, Zheng YH, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu ZM. Phosphorylation of beta-catenin by AKT promotes betacatenin transcriptional activity. J Biol Chem. 2007; 282: 11221-11229.
29. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, Dargemont C, de Herreros AG, Bellacosa A, Larue L. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007; 26:7445-7456.
30. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science. 2005; 308:1181-1184.
31. Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol. 2007; 9:210-217.
32. Kurrey NK, K A, Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol. 2005; 97:155-165.
33. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005; 8:197-209.
34. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, Marshall FF, Zhau HE, Chung LW. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 2008; 18:858-870.
35. Saitoh M, Shirakihara T, Miyazono K. Regulation of the stability of cell surface E-cadherin by the proteasome. Biochem Biophys Res Commun. 2009; 381:560-565.
36. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene. 2009; 28: 3573-3585.
37. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009; 105:109.